Pictet Asset Management Holding SA trimmed its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 6.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,517,636 shares of the biopharmaceutical company's stock after selling 110,241 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.51% of Amicus Therapeutics worth $14,296,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Xponance Inc. raised its holdings in shares of Amicus Therapeutics by 11.9% in the 4th quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company's stock worth $200,000 after purchasing an additional 2,249 shares during the period. KBC Group NV raised its stake in shares of Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after buying an additional 3,120 shares during the period. Swiss National Bank lifted its position in shares of Amicus Therapeutics by 0.7% during the 4th quarter. Swiss National Bank now owns 437,500 shares of the biopharmaceutical company's stock valued at $4,121,000 after buying an additional 3,200 shares during the last quarter. Legacy Capital Group California Inc. grew its stake in shares of Amicus Therapeutics by 20.2% during the 4th quarter. Legacy Capital Group California Inc. now owns 23,229 shares of the biopharmaceutical company's stock worth $219,000 after acquiring an additional 3,900 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Amicus Therapeutics in the 3rd quarter worth about $55,000.
Amicus Therapeutics Price Performance
Shares of NASDAQ:FOLD traded down $0.50 on Friday, hitting $7.50. The company's stock had a trading volume of 3,184,754 shares, compared to its average volume of 2,537,963. The company has a 50-day simple moving average of $9.16 and a 200 day simple moving average of $9.88. The company has a market capitalization of $2.30 billion, a PE ratio of -41.67, a PEG ratio of 1.51 and a beta of 0.69. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. Amicus Therapeutics, Inc. has a 1 year low of $7.39 and a 1 year high of $12.65.
Analysts Set New Price Targets
Several research firms have recently weighed in on FOLD. Cantor Fitzgerald reiterated an "overweight" rating and issued a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. StockNews.com cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, Wells Fargo & Company dropped their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $16.75.
Read Our Latest Report on FOLD
Amicus Therapeutics Company Profile
(
Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Featured Articles
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
